Amylx Pharmaceuticals Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.75 (market cap $2.64B), while Vanguard Total Stock Market Index Fund ETF trades at $381.72. Which is the better fit depends on your goals.
| AMLX | VTI | |
|---|---|---|
Market Cap | $2.64B | — |
Sector | Health | — |
52-Week High | $24.19 | $381.78 |
52-Week Low | $7.82 | $311.68 |
Enterprise Value | $2.39B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VTI trades at $381.85, up 0.06% with a bullish technical signal from moving averages. The ETF maintains broad diversification across 3,500+ US stocks with a low 0.03% expense ratio. Recent institutional activity shows mixed positioning with some firms increasing holdings while others reduced exposure.
The outlook remains positive given VTI's role as a core total market holding, though the elevated RSI suggests potential near-term consolidation. Key risks include market concentration in large-cap tech and broader economic volatility affecting overall equity performance.
Trailing returns across standard periods
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →